Home

SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.

CIK 1392309 · last filed 2019-03-06

SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. is a corporate insider who has filed 2 SEC Form 4 insider transactions across 2 companies since 2013. The most recent filing shows the insider sold $7.0M of KALV on Mar 6, 2019. Across all open-market trades the lifetime net is −$7.0M, making them a net seller over the disclosed history. The firm reports its address in Boston, MA. 31 SEC filings were submitted jointly with SV LIFE SCIENCES FUND IV, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

2

Lifetime Open-Market Net

-$6.95M

Filer Profile

Reported Address
ONE BOSTON PLACE
201 WASHINGTON STREET, SUITE 3900
BOSTON, MA 02108
Phone
(617) 367-8100
Formerly Known As
SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS L P (2007–2010)
Related Filers
SV LIFE SCIENCES FUND IV, L.P. — 31 joint filings, latest 2019-04-10
SVLSF IV, LLC — 31 joint filings, latest 2019-04-10
SV Life Sciences Fund IV (GP), L.P. — 30 joint filings, latest 2019-04-10
INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. — 3 joint filings, latest 2017-02-02
INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. — 3 joint filings, latest 2017-02-02
ILSF III, LLC — 2 joint filings, latest 2015-02-04
Opaleye Management Inc. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KalVista Pharmaceuticals, Inc. (KALV) Delisted 10%+ Owner 2,191,576 $27.00 $59.17M -$6.95M 1 2019-03-06
IVERIC bio, Inc. (OPHT) Delisted 10%+ Owner 11,406,831 — — $0 1 2013-10-02

Recent Filings

2 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-03-06 KalVista Pharmaceuticals, Inc. (KALV) Delisted Sell (S) −302,840 -$6.95M EDGAR
2013-10-02 IVERIC bio, Inc. (OPHT) Delisted Conv (C) +69,398,928 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.